ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Inclusion Criteria:

Documented TTR mutation
Amyloid deposits in cardiac or non-cardiac tissue
Medical history of heart failure
Evidence of cardiac involvement by echocardiogram

Exclusion Criteria:

Has known primary amyloidosis (AL), leptomeningeal amyloidosis, non-FAC hereditary cardiomyopathy, hypertensive cardiomyopathy, or cardiomyopathy due to valvular heart disease
Has known peripheral vascular disease affecting ambulation
Has a Polyneuropathy Disability score >2
Has a New York Heart Association (NYHA) classification of IV